These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18344711)

  • 21. Apolipoprotein E epsilon4 allele and familial aggregation of Alzheimer disease.
    Martinez M; Campion D; Brice A; Hannequin D; Dubois B; Didierjean O; Michon A; Thomas-Anterion C; Puel M; Frebourg T; Agid Y; Clerget-Darpoux F
    Arch Neurol; 1998 Jun; 55(6):810-6. PubMed ID: 9626772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Familial Alzheimer disease in Latinos: interaction between APOE, stroke, and estrogen replacement.
    Rippon GA; Tang MX; Lee JH; Lantigua R; Medrano M; Mayeux R
    Neurology; 2006 Jan; 66(1):35-40. PubMed ID: 16401842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "Well, good luck with that": reactions to learning of increased genetic risk for Alzheimer disease.
    Zallen DT
    Genet Med; 2018 Nov; 20(11):1462-1467. PubMed ID: 29517767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apolipoprotein E and the neuropathology of Alzheimer's disease.
    Mirra SS
    Hum Pathol; 1999 Oct; 30(10):1125-7. PubMed ID: 10534156
    [No Abstract]   [Full Text] [Related]  

  • 25. Special issues in genetic testing for Alzheimer disease.
    Greely HT
    Genet Test; 1999; 3(1):115-9. PubMed ID: 10464585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: the REVEAL Study.
    Eckert SL; Katzen H; Roberts JS; Barber M; Ravdin LD; Relkin NR; Whitehouse PJ; Green RC
    Genet Med; 2006 Dec; 8(12):746-51. PubMed ID: 17172937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging.
    Klages JD; Fisk JD; Rockwood K
    Dement Geriatr Cogn Disord; 2003; 15(1):1-5. PubMed ID: 12457072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perceived loss of memory ability and cerebral metabolic decline in persons with the apolipoprotein E-IV genetic risk for Alzheimer disease.
    Ercoli L; Siddarth P; Huang SC; Miller K; Bookheimer SY; Wright BC; Phelps ME; Small G
    Arch Gen Psychiatry; 2006 Apr; 63(4):442-8. PubMed ID: 16585474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TP73 allelic expression in human brain and allele frequencies in Alzheimer's disease.
    Li Q; Athan ES; Wei M; Yuan E; Rice SL; Vonsattel JP; Mayeux RP; Tycko B
    BMC Med Genet; 2004 Jun; 5():14. PubMed ID: 15175114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk.
    Gooding HC; Linnenbringer EL; Burack J; Roberts JS; Green RC; Biesecker BB
    Patient Educ Couns; 2006 Dec; 64(1-3):259-67. PubMed ID: 16860524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease.
    West HL; Rebeck GW; Hyman BT
    Neurosci Lett; 1994 Jul; 175(1-2):46-8. PubMed ID: 7970208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial.
    Christensen KD; Roberts JS; Whitehouse PJ; Royal CD; Obisesan TO; Cupples LA; Vernarelli JA; Bhatt DL; Linnenbringer E; Butson MB; Fasaye GA; Uhlmann WR; Hiraki S; Wang N; Cook-Deegan R; Green RC;
    Ann Intern Med; 2016 Feb; 164(3):155-63. PubMed ID: 26810768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nature throws curveballs: APOE and nonlinear decline in Alzheimer disease.
    Camicioli R; Kryscio R
    Neurology; 2005 Dec; 65(12):1855-6. PubMed ID: 16380605
    [No Abstract]   [Full Text] [Related]  

  • 34. Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex.
    Bickeböller H; Campion D; Brice A; Amouyel P; Hannequin D; Didierjean O; Penet C; Martin C; Pérez-Tur J; Michon A; Dubois B; Ledoze F; Thomas-Anterion C; Pasquier F; Puel M; Demonet JF; Moreaud O; Babron MC; Meulien D; Guez D; Chartier-Harlin MC; Frebourg T; Agid Y; Martinez M; Clerget-Darpoux F
    Am J Hum Genet; 1997 Feb; 60(2):439-46. PubMed ID: 9012418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alzheimer's disease: clinical implications of the apolipoprotein E genotype.
    Farlow MR
    Neurology; 1997 May; 48(5 Suppl 6):S30-4. PubMed ID: 9153158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Apolipoprotein E and disease].
    Pedro-Botet J; Rubiés-Prat J
    Med Clin (Barc); 1997 Jul; 109(6):216-8. PubMed ID: 9289551
    [No Abstract]   [Full Text] [Related]  

  • 37. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging.
    Hsiung GY; Sadovnick AD; Feldman H
    CMAJ; 2004 Oct; 171(8):863-7. PubMed ID: 15477624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study.
    Yip AG; Green RC; Huyck M; Cupples LA; Farrer LA;
    BMC Geriatr; 2005 Jan; 5():2. PubMed ID: 15647106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding probabilistic risk in predisposition genetic testing for Alzheimer disease.
    Koenig BA; Silverberg HL
    Genet Test; 1999; 3(1):55-63. PubMed ID: 10464578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease.
    Cassidy MR; Roberts JS; Bird TD; Steinbart EJ; Cupples LA; Chen CA; Linnenbringer E; Green RC
    Alzheimers Dement; 2008 Nov; 4(6):406-13. PubMed ID: 19012865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.